The potential role of nano- and micro-technology in the management of critical illnesses

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


In recent years nanomedicine has become an attractive concept for the targeted delivery of therapeutic and diagnostic compounds to injured or inflamed organs. Nanoscale drug delivery systems have the ability to improve the pharmacokinetics and increase the biodistribution of therapeutic agents to target organs, thereby resulting in improved efficacy and reduced drug toxicity. These systems are exploited for therapeutic purposes to carry the drug in the body in a controlled manner from the site of administration to the therapeutic target. The mortality in many of the critical illnesses such as sepsis and acute respiratory distress syndrome continues to remain high despite of an increased understanding of the molecular pathogenesis of these diseases. Several promising targets that have been identified as potential therapies for these devastating diseases have been limited because of difficulty with delivery systems. In particular, delivery of peptides, proteins, and miRNAs to the lung is an ongoing challenge. Hence, it is an attractive strategy to test potential targets by employing nanotechnology. Here some of the novel nanomedicine approaches that have been proposed and studied in recent years to facilitate the delivery of therapeutic agents in the setting of critical illnesses such as acute respiratory distress syndrome, sepsis and ventilator associated pneumonia are reviewed.

Original languageEnglish (US)
Pages (from-to)27-31
Number of pages5
JournalAdvanced Drug Delivery Reviews
StatePublished - Nov 20 2014
Externally publishedYes


  • Critical illness
  • Lung injury
  • Nanomedicine
  • Pneumonia
  • Sepsis

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'The potential role of nano- and micro-technology in the management of critical illnesses'. Together they form a unique fingerprint.

Cite this